Categories: Health

HUTCHMED to Announce 2025 Final Results

 | Source: HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
     Ben Atwell / Tim Stamper      +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
GlobeNews Wire

Recent Posts

NYSE Content Update: ‘Patty’ at Center of Burger King’s New BK Assistant AI Solution

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Feb. 26, 2026…

5 hours ago

Hettich to Unveil New Innovations at Indiawood 2026, Showcasing Its Vision for Future Living and Workspaces

As industry leaders and design professionals gear up for Indiawood 2026, Hettich is preparing to…

5 hours ago

weBoost Named Winner in 2026 Merit Awards for Telecom & Wireless

ST. GEORGE, Utah, Feb. 26, 2026 (GLOBE NEWSWIRE) -- weBoost, the leader in cell signal…

6 hours ago

Ataccama Launches Agentic Data Observability to Extend Market-Leading Data Trust Platform

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ataccama, the data trust company, today announced Agentic…

6 hours ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf…

6 hours ago